LGND - Ligand Pharmaceuticals Incorporated

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Show:
Income Statement
Balance Sheet
Cash Flow
Annual

Income Statement

All numbers in thousands
Breakdown
ttm
12/30/2018
12/30/2017
12/30/2016
Total Revenue
152,869
251,453
141,102
108,973
Cost of Revenue
12,365
6,337
5,366
5,571
Gross Profit
140,504
245,116
135,736
103,402
Operating Expenses
Research Development
46,084
27,863
26,887
21,221
Selling General and Administrative
42,770
37,734
28,653
26,621
Total Operating Expenses
102,897
81,389
67,660
58,485
Operating Income or Loss
37,607
163,727
68,076
44,917
Interest Expense
47,054
48,276
-
-
Total Other Income/Expenses Net
729,994
43,880
-10,845
-36,957
Income Before Tax
748,025
173,330
57,231
7,960
Income Tax Expense
153,840
30,009
44,675
10,327
Income from Continuing Operations
594,185
143,321
12,556
-2,367
Net Income
594,185
143,321
12,556
-1,636
Net Income available to common shareholders
594,185
143,321
12,556
-1,636
Reported EPS
Basic
-
6.77
0.60
-0.08
Diluted
-
5.96
0.53
-0.08
Weighted average shares outstanding
Basic
-
21,160
21,032
20,831
Diluted
-
24,067
23,481
20,831
EBITDA
-
179,519
80,196
55,560